Atorvastatin: Beyond lipid-lowering effects in the diabetic population

Julie Ramos; Qamar A. Khan; Martin Thoenes; Bobby V. Khan

doi:10.2217/14796678.2.5.527

Atorvastatin: Beyond lipid-lowering effects in the diabetic population

Julie Ramos, Qamar A. Khan, Martin Thoenes, Bobby V. Khan

Research output: Contribution to journal › Article › peer-review

Abstract

Statins are the mainstay of therapy in coronary artery disease and hypercholesterolemia. Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor that is taken once daily. It has been shown to considerably reduce cardiovascular mortality events. Recently, several trials have demonstrated that atorvastatin has pleiotropic effects beyond its lipid-lowering capacities. Atorvastatin is especially beneficial in diabetics for stroke prevention and improving cardiovascular mortality risk.

Original language	English (US)
Pages (from-to)	527-533
Number of pages	7
Journal	Future Cardiology
Volume	2
Issue number	5
DOIs	https://doi.org/10.2217/14796678.2.5.527
State	Published - Sep 2006
Externally published	Yes

Keywords

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Atorvastatin
Cerebrovascular accident
Coronary heart disease
Diabetes mellitus

ASJC Scopus subject areas

Molecular Medicine
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/14796678.2.5.527

Cite this

@article{fc3869bf72824855b8ca9f357ff826e4,

title = "Atorvastatin: Beyond lipid-lowering effects in the diabetic population",

abstract = "Statins are the mainstay of therapy in coronary artery disease and hypercholesterolemia. Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor that is taken once daily. It has been shown to considerably reduce cardiovascular mortality events. Recently, several trials have demonstrated that atorvastatin has pleiotropic effects beyond its lipid-lowering capacities. Atorvastatin is especially beneficial in diabetics for stroke prevention and improving cardiovascular mortality risk.",

keywords = "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, Atorvastatin, Cerebrovascular accident, Coronary heart disease, Diabetes mellitus",

author = "Julie Ramos and Khan, {Qamar A.} and Martin Thoenes and Khan, {Bobby V.}",

year = "2006",

month = sep,

doi = "10.2217/14796678.2.5.527",

language = "English (US)",

volume = "2",

pages = "527--533",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Atorvastatin

T2 - Beyond lipid-lowering effects in the diabetic population

AU - Ramos, Julie

AU - Khan, Qamar A.

AU - Thoenes, Martin

AU - Khan, Bobby V.

PY - 2006/9

Y1 - 2006/9

N2 - Statins are the mainstay of therapy in coronary artery disease and hypercholesterolemia. Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor that is taken once daily. It has been shown to considerably reduce cardiovascular mortality events. Recently, several trials have demonstrated that atorvastatin has pleiotropic effects beyond its lipid-lowering capacities. Atorvastatin is especially beneficial in diabetics for stroke prevention and improving cardiovascular mortality risk.

AB - Statins are the mainstay of therapy in coronary artery disease and hypercholesterolemia. Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor that is taken once daily. It has been shown to considerably reduce cardiovascular mortality events. Recently, several trials have demonstrated that atorvastatin has pleiotropic effects beyond its lipid-lowering capacities. Atorvastatin is especially beneficial in diabetics for stroke prevention and improving cardiovascular mortality risk.

KW - 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

KW - Atorvastatin

KW - Cerebrovascular accident

KW - Coronary heart disease

KW - Diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=33749546256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749546256&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.5.527

DO - 10.2217/14796678.2.5.527

M3 - Article

C2 - 19804188

AN - SCOPUS:33749546256

SN - 1479-6678

VL - 2

SP - 527

EP - 533

JO - Future Cardiology

JF - Future Cardiology

IS - 5

ER -

Atorvastatin: Beyond lipid-lowering effects in the diabetic population

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this